INM
Sponsored by LFG Equities Corp and Disseminated on Behalf of Inmed Pharmaceuticals
Finviz has the Float a TINY 1.2 Mill, highlighting the ability to easily move
InMed’s strong pipeline of treatments, from preclinical stages through Phase 2 trials, showcases the company’s long-term potential and strategic foresight
INM's Subsidiary Baymedica is Generating Nearly $5Mill in Revenues
Check Out the Investor Presentation HERE
*****BREAKING NEWS THIS MORNING *****
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
June 24, 2025 7:00 AM EDT
- Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro
- Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegeneration
- Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology
Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer's disease.
The study evaluated INM-901 in an ex vivo model of lipopolysaccharide (LPS)-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro and inflammasome marker NLRP3. Results demonstrated that INM-901 treatment can reduce pro-inflammatory cytokines and may have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation. This study model offers insight into INM-901's potential therapeutic impact on brain inflammation that may underlie a broad range of neurodegenerative diseases, including Alzheimer's disease.
Key Findings from the Study:
- INM-901 significantly reduced levels of NLRP3 and IL-1β, two inflammasome markers increasingly implicated in the pathogenesis of Alzheimer's disease and other neuroinflammatory diseases.
- INM-901 treatment resulted in a dose-dependent and statistically significant reduction in several key pro-inflammatory markers, including IL-6, IL-1β, KC/Gro, and IL-2.
- INM-901 reduced key pro-inflammatory markers, independent of amyloid-beta or tau pathology, signifying potential to treat other dementia-related diseases.
"NLRP3-driven inflammation is recognized as a key contributor to neurodegenerative disease progression," said Dr. Eric Hsu, SVP of Preclinical Research & Development. "The data derived from this LPS-induced inflammation study further support our previous findings in the amyloid beta animal model following INM-901 treatment, which demonstrated a significant reduction in inflammatory markers. Notably, the results from the LPS study suggest that INM-901 exerts a direct effect on neuroinflammation, independent of the contributions from amyloid beta plaques or tau aggregation."
NLRP3 has been implicated in the pathogenesis of several inflammatory, autoimmune, metabolic and neurodegenerative conditions such as Alzheimer's disease, Parkinson's, type 2 diabetes and others. In these diseases, overactivation of NLRP3 can result in chronic inflammation in the brain, which may contribute to neurodegeneration and cognitive decline.
This most recent study represents a key advancement for the program, highlighting INM-901 as a distinctive and promising therapeutic candidate for the treatment of Alzheimer's disease and supports continued development toward a lead indication in Alzheimer's disease. The Company plans to advance INM-901 through additional preclinical studies, with IND-enabling studies to follow.
INM-901: Program Summary to date:
INM-901 is a proprietary small molecule drug candidate for Alzheimer's disease with potentially multiple mechanisms of action. Key characteristics of INM-901 include:
- demonstrates reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer's disease;
- is a preferential signaling agonist of the CB1/CB2 receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death;
- impacts the peroxisome proliferator-activated receptors ("PPARs"), which have been shown to play an important role in diabetes and are also considered as one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer's disease;
- can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection, offering many potential advantages over routes of administration of the currently approved products; and
- demonstrates significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior and sound awareness in long-term preclinical behavioural studies.
To learn more about INM-901, please visit the website at: https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimers-disease/.
_________________________
Hello Everyone,
Today's profile exploded all the way to 11 bucks. It closed up .55 on the day. We are going to watch that one like a Hawk and don't think that's the last time we will be talking about it.
Moving on to tomorrow's profile. Now this is a company that we haven't looked at in few years. We think right now is a great time to go ahead and research INM.
The float could play a major factor in how INM performs in the coming weeks.
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s disease and ocular and dermatological indications. InMed Pharmaceuticals is not just another biotech firm; it’s a company with the potential to redefine the treatment landscape for Alzheimer’s disease.
INM is an extremely unique hybrid company. They have several pharmaceutical programs supported by a revenue generating business.
INM uses a patented form of cannabinoid molecules. These molecules originally found in Cannabis have long been known for its medicinal properties, including its ability to reduce inflammation, improve symptoms of chronic diseases, and even show potential in cancer treatment. Several studies have pointed to the neuroprotective effects of cannabinoids which protect brain cells from damage, preserving cognition with is incredibly important for neurodegenerative diseases such as Alzheimer’s. However, the use of cannabinoids in medicine has been limited due to legal and regulatory concerns.
InMed is addressing this challenge by modifying natural cannabinoids to create super effective
molecules that could offer even greater therapeutic benefits. These cannabinoid molecules are naturally occurring… however when modified by InMed, their effect could potentially be a game changer for Alzheimer’s disease.
In fact, their treatment, INM-901, is the result of this innovative approach. And what’s incredible is InMed has patented the actual molecules in their treatment, protecting themselves against competitors using identical compounds.
This is the exact type of approach that could get Big Pharma to become a customer rather than a competitor.
Thanks to its unique patented molecules and INM-901 treatment… the potential for success is sky high with this company.
And as the race to tackle Alzheimer’s intensifies, InMed’s innovative approach and strategic positioning make it a standout player in a rapidly growing market.
We know this one can FLY. Just a few weeks ago in early June it ran to 8 bucks on $450 Mill with zero news to speak of. It just got going with some momentum.
INM has the potential to move because it roughly has a market cap OF $3.3M give or take. The valuation might be what really stands out to you. If you can believe it they are sitting below their current cash and have a profitable subsidiary generating roughly $5 million in annual revenue. What INM brings to the table for their investors is exposure to a full pharmaceutical pipeline and commercial subsidiary at essentially no enterprise value.
INM has 3 therapeutic programs in development. The most promising asset may be INM-901, a proprietary oral small molecule targeting Alzheimer’s disease. This represents one of the largest and most underserved markets in medicine.
INM Alzheimer’s Preclinical Program Highlights:
• Addressing multiple pathologies related to Alzheimer’s Disease
• Reduce neuroinflammation and enhance neuronal functioning in the brain potentially reversing the damage caused by Alzheimer’s disease.
• Importantly, INM-901 may be delivered orally where most drugs in Alzheimer’s need to be administered through IV, which can be very costly and challenging.
• Safely and effectively cross the blood/brain barrier, delivering the drug molecule directly to the brain.
• Successfully crossing the blood/brain barrier is a major challenge to the industry and is important in offering treatment to diseases such as Alzheimer’s.
• Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness in vivo studies – All major hallmarks of this devastating disease.
• Statistically significant reductions in inflammatory and neurodegeneration biomarkers
• Cost-effective, which is increasingly important as the healthcare system looks to balance innovation with accessibility INM-089: Advancing a Novel Approach in Dry AMD
• INM-089 is InMed’s proprietary small molecule drug candidate targeting dry age-related macular degeneration (AMD)—a condition with no FDA-approved treatment options and affecting over 150 million people globally.
Completed a phase 2 clinical trial in the treatment of Epidermolysis bullosa – Currently seeking strategic partnership for further advancement.
INM Has Built in Insurance with revenue generating & profitable subsidiary BayMedica
While many preclinical-stage biotech companies are entirely reliant on external capital, InMed reduces investor risk through BayMedica, its commercial arm. This division is cash-flow positive and positioned for potential divestiture, spin-out, or growth partnership—unlocking hidden value.
Undervalued: With a market cap less than its cash position, active revenue stream, disease-modifying Alzheimer’s drug candidate, InMed (NASDAQ: INM) represents a rare value in today’s biotech landscape.
One of the biggest challenges with current Alzheimer’s treatments is while they may slow the rate of cognitive decline, none have been shown to halt or reverse its progression.
Not to mention some of these recently-approved drugs come with major treatment limitations that are incredibly costly and inconvenient for patients.
In fact, most of these treatments only focus on one thing; reducing Amyloid beta plaque.
However, new research suggests this plaque is not the cause of Alzheimer’s and instead is a Symptom. That means hundreds of millions of dollars and decades of patient trials haven’t been able to offer a comprehensive cure. In fact, new research suggest the most effective way to treat Alzheimer’s will require a multitude of therapies, not a silver bullet.
This is where InMed’s unique approach comes in!
Not only do their previous preclinical studies show a reduction in amyloid beta plaque but it also shows the potential to be diseases modifying by:
Addressing multiple pathologies related to Alzheimer’s Disease Reduce neuroinflammation and enhances neuronal functioning in the brain potentially reversing the damage caused by Alzheimer’s disease.
Importantly, INM-901 may be delivered orally where most drugs in Alzheimer’s need to be administered through IV, which can be very costly and challenging. Safely and effectively cross the blood/brain barrier, delivering the drug molecule directly to the brain.
Successfully crossing the blood/brain barrier is a major challenge to the industry and is important in offering treatment to diseases such as Alzheimer’s.
Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness – All major hallmarks of this devastating Disease. But one of the most exciting developments for INM is the data supporting the growth of neurites. This allows for better cell to cell to communicate within the brain.
In simple terms, this development may indicate the potential to reverse neuronal damage.
An incredible feat that has not been seen in any other treatment available today.
You read that right. This tiny $3M microcap is demonstrating cutting edge developments in Alzheimer’s treatments. Also the fact that this molecule can be formulated orally is a HUGE advantage. Current treatment options utilizing large molecules often come with serious side effects, such as brain inflammation and bleeding, necessitating periodic brain scans—typically once or twice annually—to monitor these risks. In contrast, small molecule drug candidates present numerous advantages over existing therapies. InMed aims to develop an effective, disease-modifying treatment that is orally administered, ensuring greater accessibility for patients.
NEWS
Jun 13, 2025
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
May 12, 2025
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 12, 2025
Feb 3, 2025
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
Jan 22, 2025
Jan 21, 2025
InMed Announces Results of 2024 Annual General Meeting
Dec 18, 2024
InMed Enters Into Standby Equity Purchase Agreement
Dec 17, 2024
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
Nov 19, 2024
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Nov 14, 2024
MANAGEMENT
Eric A. Adams, MIBS
Chief Executive Officer & President
Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in
capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well-respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies. He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Michael Woudenberg, P.Eng.
Chief Operating Officer
Mr. Woudenberg joined InMed with more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He brings valuable expertise in the development, technology transfer and commercialization of
active pharmaceutical ingredients (APIs) and drug products. Prior to joining InMed in 2018, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC. His experience includes process and formulation development from lab/pre-clinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g. FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products.Mr. Woudenberg received his Bachelor of Science, Chemistry and Bachelor of Engineering Science, Chemical at Western University of London, Ontario, Canada.
Netta Jagpal, CPA
Chief Financial Officer
Ms. Jagpal joins InMed with over 20 years of experience in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS) where she led a finance team through the initial public offering process.
Prior to D-Wave, Netta spent 11 years at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behaviour from Simon Fraser University.
Eric C. Hsu, PhD
Senior Vice President, Pre-Clinical Research & Development
Dr. Hsu joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations.
Dr. Hsu's experience includes a wide array of activities, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines, and managing R&D budgets and timelines. Dr. Hsu is considered to be an expert in gene transfer and gene expression using vector systems.Dr. Hsu received his Doctorate from the Department of Medical Biophysics at the University of Toronto and his Bachelor’s degree from McGill University.
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY INM PROFILE ON 6/24/25.
WE HAVE PREVIOUSLY BEEN COMPENSATED TWELVE THOUSAND FIVE HUNDRED DOLLARS DIRECTLY BY THE ISSUER. WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD FOR 1 ONE DAY AWARENESS CAMPAIGNS BY A THIRD PARTY, NORTH EQUITIES CORP BACK ON NOVEMBER 08 2022. WE HAVE PREVIOUSLY BEEN COMPENSATED AN ADDITIONAL FIVE THOUSAND DOLLARS DIRECTLY BY THE ISSUER.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.